In alignment with this year’s meeting theme of “Putting Patients First”, we are pleased to present the patient-friendly benefits of the HyFoSy Procedure and ExEm^® Foam, a clinically-proven and gentle ultrasound tubal patency assessment for women with known or suspected infertility.

RSVP for a one-on-one demo and meet with a team member for information on:

• In-clinic HyFoSy training opportunities
• HyFoSy ultrasound imaging samples
• New programs to benefit your clinic(s) and patients
• Product samples

Join clinics around the world redefining advanced tubal patency testing and reshaping patient care through the HyFoSy Procedure, RSVP HERE.

About the Pacific Coast Reproductive Society (PCRS)
PCRS is a global, interactive organization that champions the field of reproductive medicine. PCRS believes in the core values of supportiveness, innovation, inclusiveness, collegiality, professional and personal development, and intimacy. The organization is a multidisciplinary medical specialty society providing Continuing Medical Education (CME) to physicians and allied healthcare professionals. PCRS offers the highest quality, innovative CME, designed and presented by thought leaders in reproductive medicine. It provides an outstanding forum for the exchange of information, and the advancement of the ideologies in reproductive medicine in a relaxed and collegial setting building relationships that foster the integration of current knowledge to ensure quality medical care for patients.

To learn more about PCRS and the PCRS 2023 Annual Meeting, visit: https://pcrs.memberclicks.net

About ExEm^® Foam (air polymer-type A) intrauterine foam
ExEm^® Foam ((air polymer-type A) intrauterine foam) is an innovative, FDA-approved product for use in the hysterosalpingo foam sonography (or HyFoSy). The HyFoSy Procedure is a gentle ultrasound tubal patency assessment for women with known or suspected infertility. During the HyFoSy procedure, ExEm^® Foam is infused into the uterus by a healthcare professional and scanned via ultrasound technology to produce a highly echogenic visual assessment of fallopian tubes. If the tubes are patent the foam will be visualized through ultrasound as a thin, bright white line within the fallopian tubes, and will spill over the ovaries and into the peritoneal. If the white line does not appear, the fallopian tubes might be occluded or blocked.

IMPORTANT SAFETY INFORMATION
ExEm^® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting.

Click here for full prescribing information.

‍About ExEm^® Foam Inc
ExEm^® Foam Inc. is focused on providing solutions to simplify infertility diagnosis and enhance the fertility journey. Drawing on its years of experience, the team develops innovative products that better meet the needs of today’s patient and healthcare professional. ExEm^® Foam, the company’s first FDA-approved product, is indicated as a contrast drug for hysterosalpingo foam sonography, also known as HyFoSy, to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. ExEm^® Foam has been used in more than 1,000,000 tubal patency procedures worldwide since it first launched in Europe in 2011. ExEm^® Foam Inc. is headquartered in Nashville, TN.

For more information, please visit www.exemfoam.com.